Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 3, 2002, Pages 186-192

  Ding, Qi ^a   Kestell, Philip ^a   Baguley, Bruce C ^a   Palmer, Brian D ^a   Paxton, James W ^b   Muller, George ^c   Ching, Lai Ming ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c CELGENE CORPORATION   (United States)

Author keywords

Antitumour; Colon 38; Cyclophosphamide; Pharmacokinetics; Thalidomide

Indexed keywords

2 DECHLOROETHYLCYCLOPHOSPHAMIDE; 4 HYDROXYCYCLOPHOSPHAMIDE; 4 OXOCYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE; DRUG METABOLITE; THALIDOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; COLON TUMOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG LIVER LEVEL; DRUG POTENTIATION; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; COLONIC NEOPLASMS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL;

EID: 0036042545     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0482-y     Document Type: Article

References (23)

1. Immunomodulatory actions of xanthenone anticancer agents
2. Thalidomide revisited: Pharmacology and clinical applications
3. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid
4. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid
5. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the antitumour agent 5,6-dimethylxanthenone-4-acetic acid: Concomitant reduction of serum tumour necrosis factor-alpha and enhancement of antitumour activity
6. Oxidative metabolism of cyclophosphamide: Identification of the hepatic monooxygenase catalysts of drug activation
7. Thalidomide is an inhibitor of angiogenesis
8. Anti-angiogenic treatment of metastatic melanoma, renal cell, ovarian and breast cancers with thalidomide: A phase II study
9. Pharmacokinetics of thalidomide in an elderly prostate cancer population
10. A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas
11. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat
12. Inhibition of NF-kappaB activity by thalidomide through suppression of I-kappaB kinase activity
13. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide
14. The saga of thalidomide
15. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity
16. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients
17. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
18. Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling
19. Thalidomide selectively inhibits tumor necrosis factor-alpha production by stimulated human monocytes
20. Antitumour activity of thalidomide in refractory multiple myeloma
21. Pharmacokinetics of "activated" cyclophosphamide and therapeutic efficacies
22. Role of cytochrome P450 in oxazaphosphorine metabolism
23. A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide